Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > JD still can't admit it
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(90)
•••
Comment by TheTruth1234on Nov 10, 2023 7:30pm
107 Views
Post# 35729677

RE:JD still can't admit it

RE:JD still can't admit it
zwerp2000 wrote: 15+ years of his life spent on this board, doing DD on the company etc and for what? he was wrong the entire time. and not just a little wrong.......all wrong. you can't get any more wrong than he got it. how could he be so off on his DD? what a waste of time and a life and nothing to show for it. humiliating to say the least. in the end, the stock and technology is worth nothing and JD is viewed by all as a laughable joke. 



Bingo Zwerp!


All this time ol Johnny boy thought he was the smartest man in the room.
Only he could understand the science and "connect the dots".

All his "DD"  was from his "readn' and studyn" the internet. 
Not once did he reach out to the professionals, the scientists etc. 
He thought he was right.


Now look at the fool.


Broke, and destroyed financially.


You just cant make this comedy show up!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities